On Invalid Date, Biodesix (NASDAQ: BDSX) reported Q2 2023 earnings per share (EPS) of -$0.17, up 57.5% year over year. Total Biodesix earnings for the quarter were -$13.36 million. In the same quarter last year, Biodesix's earnings per share (EPS) was -$0.40.
On Invalid Date, Biodesix (NASDAQ: BDSX) reported Q2 2023 revenue of $11.87 million up 8.42% year over year. In the same quarter last year, Biodesix's revenue was $10.95 million.
What was BDSX's revenue growth in the past year?
As of Q3 2023, Biodesix's revenue has grown 33.24% year over year. This is 31.33 percentage points higher than the US Diagnostics & Research industry revenue growth rate of 1.91%. Biodesix's revenue in the past year totalled $41.64 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.